Cargando…
ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments
BACKGROUND: Cachexia affects the majority of patients with advanced cancer and is associated with reduced treatment tolerance, response to therapy, quality of life, and life expectancy. Cachectic patients with advanced cancer often receive anti-cancer therapies against their specific cancer type as...
Autores principales: | Hatakeyama, Shinji, Summermatter, Serge, Jourdain, Marie, Melly, Stefan, Minetti, Giulia C., Lach-Trifilieff, Estelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960708/ https://www.ncbi.nlm.nih.gov/pubmed/27462398 http://dx.doi.org/10.1186/s13395-016-0098-2 |
Ejemplares similares
-
Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia
por: Pettersen, Kristine, et al.
Publicado: (2019) -
Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
por: Segatto, Marco, et al.
Publicado: (2017) -
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
por: Morvan, Frederic, et al.
Publicado: (2017) -
Clinical Implications of TβRII Expression in Breast Cancer
por: Gao, Ningning, et al.
Publicado: (2015) -
Mutation of TGFβ-RII eliminates NSAID cancer chemoprevention
por: Martín-López, Juana, et al.
Publicado: (2017)